VTRS
$13.20-0.30 (-2.22%)
Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East.
Recent News
Will Viatris’ 2030 Capital Return And Growth Blueprint Change Viatris' (VTRS) Narrative
Viatris has already held an Investor Event where its leadership outlined the company’s long-term vision through 2030, including growth priorities, R&D focus, commercial strategy, portfolio management, and a financial framework intended to support revenue and earnings expansion and capital returns. A key insight from the event is Viatris’ emphasis on using anticipated product launches, its pipeline, business development, and cash flow to both return capital to shareholders and reinvest in...
What Investors Should Know About a $24 Million Exit From a Medical Device Stock Down 9% This Past Year
This medical technology firm delivers integrated blood management solutions to healthcare providers and plasma centers worldwide.
Theravance's Q4 Earnings and Revenues Miss Estimates
TBPH's posts Q4 earnings miss despite 145% revenue surge; scraps Ampreloxetine, launches restructuring and weighs a potential sale.
1 Cash-Producing Stock to Target This Week and 2 That Underwhelm
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
What Are Analysts Saying About Viatris Inc (VTRS) Stock?
Viatris Inc. (NASDAQ:VTRS) is one of the 13 extreme value stocks to buy now. Viatris Inc. (NASDAQ:VTRS) is covered by 12 analysts on Wall Street with a medium price target of $16, suggesting 12.36% upside from current levels. On February 27, Truist Financial analyst Les Sulewski raised the firm’s price target on the stock from […]